Analogous to LDL-c, the lower the better also seems true for inflammation

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

AHA 2017 A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but response to treatment did.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the AHA 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.

Faculty

Prof. Paul Ridker is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital. A cardiovascular medicine specialist, and Eugene Braunwald Professor of Medicine at Harvard School of Medicine.

Disclosures

- Our reporting is based on the information provided at the AHA 2017 congress -

Read our reporting on this analysis

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.